EC Number   |
Activating Compound |
Reference |
|---|
   3.4.21.79 | A23187 |
induces granzyme B expression in mast cell lines HMC-1 and LAD2 and cord blood-derived mast cells |
681967 |
| 3.4.21.79 | cathepsin C |
proteolytically activates in cytotoxic granules |
679007 |
| 3.4.21.79 | compound 48/80 |
induces granzyme B expression in mast cell line LAD2 and cord blood-derived mast cells |
681967 |
| 3.4.21.79 | ionomycin |
stimulates |
682965 |
| 3.4.21.79 | more |
activation of CD4+ T cells with anti-CD3 and anti-CD28 or anti-CD46 induces granzyme B expression in all cells. Granzyme B expression in anti-CD3/anti-CD46 activated CD4+ T cells is much higher than granzyme B expression induced by usual activation (anti-CD3/anti-CD28) |
698224 |
| 3.4.21.79 | more |
an extracellular activator of granzyme B may exist |
698217 |
| 3.4.21.79 | more |
CMV/EBV/influenza peptide pool peptides do not induce GzB release in CD8+ cells from healthy donors within 24 h. Purified CD8+ cells after CMV/EBV/influenza peptide pool peptide stimulation show induction of GzB after 72 h in vitro. HIV peptides induce GzB secretion in HIV-infected individuals directly ex vivo |
677431 |
| 3.4.21.79 | more |
granzyme B expression in Treg cells is activated by syngeneic tumor cell line |
680104 |
| 3.4.21.79 | more |
granzyme B level is elevated in the early stage of Rasmussen syndrome around the onset of epilepsy and remains slightly elevated even in the progressed stage, and declines within a few months to more or less constant levels |
697673 |
| 3.4.21.79 | more |
GzB is not induced in purified CD8+ cells by CEF peptides ex vivo. Low frequencies of GzB producing CD8+ cells after mitogen stimulation. IFN-gamma positive, GzB negative CD8+ memory cells convert into GzB producing cells within 2 days after antigen stimulation. Induction of GzB producing CD8+ cells after Vaccinia virus booster immunization. HIV peptides induce GzB production in HIV-infected individuals directly ex vivo |
679116 |
